ALTO NEUROSCIENCE reports phase 2 trial of ALTO-101 misses primary endpoint

April 1, 2026 4:30 PM

Alto Neuroscience Inc. (NYSE: ANRO) announced that its Phase 2 proof-of-concept trial of ALTO-101 for cognitive impairment associated with schizophrenia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found